Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
Just one more system” often increases total cost by adding integration work, risk, and slowdowns you don’t see on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback